Rezdiffra (Resmetirom) and Rosuvastatin Interaction: What You Need to Know

Does Resmetirom Raise Rosuvastatin Levels?

Yes. Resmetirom inhibits the hepatic uptake transporters OATP1B1 and OATP1B3, which are responsible for clearing rosuvastatin from circulation into the liver. The approved Rezdiffra prescribing information states that co-administration increased rosuvastatin area under the curve (AUC) by approximately 2-fold [1]. Because rosuvastatin's myotoxicity risk scales with plasma exposure, this interaction is clinically meaningful and requires a dose ceiling.

What OATP1B1 and OATP1B3 Actually Do

OATP1B1 (encoded by SLCO1B1) and OATP1B3 (encoded by SLCO1B3) are sodium-independent organic anion transporters expressed almost exclusively on the sinusoidal membrane of hepatocytes. Their primary job is to extract statins, bile acids, and other organic anions from portal blood and deliver them into the liver for metabolism or biliary excretion [2].

Rosuvastatin relies on OATP1B1 and OATP1B3 for a substantial fraction of its hepatic uptake. Unlike many statins, rosuvastatin undergoes minimal CYP450 metabolism (less than 10% via CYP2C9) and is not a P-glycoprotein substrate in any clinically significant way [3]. This means transporter inhibition, not enzyme inhibition, is the dominant pharmacokinetic concern with rosuvastatin.

How Resmetirom Fits In

Resmetirom is a selective thyroid hormone receptor-beta (THR-beta) agonist approved for adults with MASH and liver fibrosis stage F2 or F3 [1]. In drug interaction studies conducted by the manufacturer, resmetirom inhibited OATP1B1 and OATP1B3 in vitro and produced the roughly 2-fold AUC increase for rosuvastatin observed in clinical pharmacokinetic work referenced in the label [1]. The interaction is transporter-based, not enzyme-based. CYP3A4, CYP2C9, and P-glycoprotein are not involved in this particular pairing.

Why the 2-Fold Exposure Increase Matters for Rosuvastatin Safety

A 2-fold increase in rosuvastatin AUC is not trivial. Rosuvastatin's risk of skeletal muscle toxicity, ranging from myalgia through myopathy to the rare but serious rhabdomyolysis, is concentration-dependent [4]. The FDA originally approved rosuvastatin (Crestor) with a 40 mg maximum daily dose in most patients and restricted the 40 mg dose to those who failed lower doses, precisely because higher plasma levels correlate with higher muscle event rates [3].

Dose-Response Relationship for Statin Myopathy

A large observational analysis published in JAMA found that high-intensity statin therapy, defined as doses producing >50% LDL reduction, was associated with a significantly higher rate of muscle-related adverse events compared with moderate-intensity therapy [5]. Doubling the effective plasma exposure of rosuvastatin through transporter inhibition is pharmacologically equivalent to doubling the administered dose from the muscle's perspective.

The SLCO1B1 pharmacogenomics literature reinforces this. The SLCO1B1 521T>C variant (rs4149056), which reduces OATP1B1 function, raises simvastatin acid AUC by 221% and is listed by the Clinical Pharmacogenomics Implementation Consortium (CPIC) as a high-risk variant for statin-induced myopathy [6]. Resmetirom's inhibition of OATP1B1 mimics a pharmacological version of this transporter loss.

Rhabdomyolysis Risk Threshold

Rhabdomyolysis from statins is uncommon (estimated at 1 to 5 cases per 100,000 patient-years for standard doses) but carries a case-fatality rate of approximately 10% when renal failure develops [7]. Patients with MASH who are candidates for resmetirom therapy often carry additional myopathy risk factors: older age, hypothyroidism, chronic kidney disease, and polypharmacy. Each additional factor compounds the risk of a drug-interaction-driven exposure increase.

FDA Label Recommendations for Rosuvastatin Co-Administration

The Rezdiffra (resmetirom) prescribing information issued by Madrigal Pharmaceuticals in March 2024 explicitly addresses rosuvastatin [1]. The relevant instruction reads: limit rosuvastatin to a maximum of 20 mg per day when co-administered with resmetirom. No titration schedule or washout period is specified; the label treats 20 mg as a hard ceiling for the duration of combined use.

What the 20 mg Cap Means Clinically

A 20 mg rosuvastatin ceiling is a moderate-intensity statin regimen per the 2019 ACC/AHA cholesterol guidelines, which define moderate intensity as a daily dose expected to reduce LDL-C by 30% to 49% [8]. Patients who were previously on rosuvastatin 40 mg for aggressive LDL targets, such as those with established atherosclerotic cardiovascular disease (ASCVD) requiring high-intensity therapy, need a frank conversation about therapeutic trade-offs.

Switching to an alternative high-intensity statin that does not rely heavily on OATP1B1/1B3 is one option. Atorvastatin, for instance, is also an OATP1B1 substrate, so it carries similar interaction liability [2]. Pitavastatin is primarily eliminated via OATP1B3 and glucuronidation and may carry a different, though not zero, interaction profile. Every substitution should be weighed against the patient's cardiovascular risk and the specific interaction data for that statin with resmetirom.

Other Statins in the Rezdiffra Label

The prescribing information flags additional statins beyond rosuvastatin. Pitavastatin AUC increased approximately 2.4-fold, and the label recommends a 2 mg daily maximum during co-administration [1]. Pravastatin exposure also increases, with a recommended ceiling of 40 mg per day. Clinicians managing patients on any statin who are starting resmetirom should consult the full drug interactions table in section 7 of the label before writing prescriptions.

Mechanism Deep Dive: OATP Inhibition Versus CYP Inhibition

Understanding the distinction between transporter-mediated and enzyme-mediated interactions matters for predicting which other drugs may be affected and for counseling patients correctly.

Transporter Inhibition Mechanics

Transporter inhibitors reduce the rate of substrate uptake into cells by competing for or blocking the transporter binding site. Unlike CYP inhibition, which delays hepatic metabolism, OATP inhibition reduces hepatic extraction of the substrate from blood. The net result is similar: higher systemic drug exposure. The key difference is timing. CYP inhibition tends to accumulate over multiple doses as the enzyme is occupied; transporter inhibition can manifest after a single dose because it acts at the absorption phase [9].

For resmetirom and rosuvastatin, this means the interaction is present from the first co-administered dose. There is no "safe window" before the interaction develops.

Why CYP2C9 and CYP3A4 Are Not the Story Here

Resmetirom is metabolized primarily by CYP3A4 and CYP2C8, and it is a mild inducer of CYP3A4 [1]. Rosuvastatin's minimal CYP2C9 metabolism means resmetirom's CYP induction has no meaningful effect on rosuvastatin clearance. The interaction is almost entirely a transporter story, which is why the clinical magnitude (2-fold AUC) is so consistent and predictable.

P-Glycoprotein Considerations

Rosuvastatin is a substrate of breast cancer resistance protein (BCRP, ABCG2), not P-glycoprotein (P-gp, ABCB1). The Rezdiffra label also notes BCRP inhibition by resmetirom, which contributes to the overall magnitude of the rosuvastatin exposure increase [1]. Patients carrying the ABCG2 421C>A variant (reduced BCRP function) may be at even higher risk for elevated rosuvastatin levels when resmetirom is added, though the label does not require genotyping before initiation.

Monitoring Parameters and Clinical Workflow

The combination of resmetirom and rosuvastatin is not contraindicated, but it requires structured follow-up. A practical monitoring plan should address both the statin side and the hepatic side, given that MASH itself alters drug metabolism.

Creatine Kinase and Muscle Symptom Surveillance

Baseline CK measurement before starting the combination is good practice, though the Rezdiffra label does not mandate it as a labeling requirement. If the baseline CK is more than 5 times the upper limit of normal (ULN), most guidelines recommend holding the statin regardless of the resmetirom interaction [8].

During therapy, patients should be instructed to report any unexplained muscle pain, weakness, or dark urine within 24 to 48 hours of onset, not at their next scheduled visit. Myoglobinuria, the hallmark of rhabdomyolysis, can progress to acute kidney injury within days. Prompt CK measurement and, if markedly elevated (typically >10 times ULN with symptoms), temporary statin discontinuation is the standard response.

Liver Function in the MASH Population

Patients on resmetirom already have underlying liver disease. The MAESTRO-NASH trial (N=966), the key phase 3 study supporting resmetirom's approval, showed that 26% of patients on 100 mg resmetirom achieved MASH resolution without fibrosis worsening at 52 weeks versus 10% on placebo [10]. Liver enzyme changes in the study population were monitored closely. Co-administration of rosuvastatin at doses above the 20 mg ceiling in the context of hepatic transporter saturation could produce unpredictable hepatic exposure changes beyond the statin interaction itself.

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be checked at baseline and at 3-month intervals during combined therapy, consistent with standard MASH management practice.

Renal Function Monitoring

Rosuvastatin is approximately 90% excreted unchanged in feces, but the 10% renal elimination becomes relevant when myopathy develops. Baseline serum creatinine or estimated glomerular filtration rate (eGFR) should be documented. The FDA label for rosuvastatin (Crestor) already restricts the starting dose to 5 mg daily in patients with eGFR <30 mL/min/1.73 m², and adds further caution at higher doses [3]. Overlaying the resmetirom interaction on top of chronic kidney disease narrows the therapeutic window significantly.

Patient Counseling Points

Patients starting Rezdiffra who are already taking rosuvastatin need clear, actionable information. The clinical complexity should not translate into vague reassurances.

A practical counseling framework for this combination:

1. Dose check before day one. Confirm the rosuvastatin prescription is 20 mg or less before the first resmetirom dose is taken. Do not wait until the next refill.
2. Symptom recognition. Muscle aches that are new, diffuse, or accompanied by weakness, especially in the thighs or upper arms, require same-day contact with the prescriber, not a wait-and-see approach.
3. Dark urine is an emergency. Tea-colored or cola-colored urine while on a statin is rhabdomyolysis until proven otherwise. Patients should go to the emergency department, not call the office.
4. No dose self-adjustments. Patients should not increase rosuvastatin back to their prior dose because they "feel fine." The transporter inhibition persists for the duration of resmetirom use.
5. Other medications matter. Gemfibrozil, cyclosporine, and certain antifungals further raise rosuvastatin levels through separate mechanisms [3]. A complete medication reconciliation should occur before resmetirom initiation.
6. Dietary note. Large amounts of grapefruit juice do not meaningfully affect rosuvastatin (unlike simvastatin or lovastatin), so dietary counseling on this point is not specifically required for this combination.

The FDA's MedWatch system should be used to report any serious adverse events observed during this combination [11].

Cardiovascular Risk Context in MASH Patients

Patients with MASH carry a markedly elevated cardiovascular risk. A 2023 analysis published in the Journal of Hepatology found that cardiovascular disease, not liver-related complications, is the leading cause of mortality in patients with nonalcoholic fatty liver disease [12]. Statins are therefore often non-negotiable in this population.

The tension between maintaining effective statin therapy for cardiovascular protection and managing the pharmacokinetic interaction with resmetirom is real. Downgrading from rosuvastatin 40 mg to 20 mg may reduce LDL-C lowering by roughly 6 percentage points, given that each doubling of rosuvastatin dose produces approximately 6% additional LDL reduction per the log-linear statin dose-response [8]. For most patients, a 6-percentage-point LDL reduction gap can be addressed through the addition of ezetimibe 10 mg daily, which lowers LDL-C by an additional 18 to 24% independent of statin dose and does not interact with OATP1B1 [13].

Alternatively, evolocumab or alirocumab (PCSK9 inhibitors) can be added to a moderate-intensity statin if the LDL-C target is not met, with no known pharmacokinetic interaction with resmetirom [13].

Summary of Dose Adjustments for All Resmetirom-Affected Statins

The table below summarizes FDA label guidance for statins co-administered with resmetirom 80 mg or 100 mg daily.

| Statin | AUC Increase (Approximate) | Maximum Recommended Daily Dose | |---|---|---| | Rosuvastatin | ~2-fold | 20 mg | | Pitavastatin | ~2.4-fold | 2 mg | | Pravastatin | Increased (magnitude varies) | 40 mg | | Atorvastatin | OATP substrate; monitor | Per clinical judgment | | Simvastatin | OATP/CYP3A4 substrate | Per clinical judgment |

Source: Rezdiffra (resmetirom) full prescribing information, Madrigal Pharmaceuticals, March 2024 [1].

Clinicians should note that the atorvastatin and simvastatin rows reflect general OATP substrate considerations; specific fold-increases from clinical studies with resmetirom are detailed in the full label section 12.3 [1].